Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Despite guidelines addressing overdetection, no significant declines are seen; emphasis on active surveillance approaches is ...

Immune checkpoint inhibitors (ICIs), a major type of cancer immunotherapy, don't do much for hospitalized cancer patients, ...

Researchers at The Tisch Cancer Institute at Mount Sinai have uncovered a major reason why some colorectal cancers (CRC) ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...